MENA

Kidney on a chip technology
#Europe #Hansa Biopharma #License agreement #MENA

Hansa closes €115m licensing transaction for Idefirix 

Hansa Biopharma has closed a €115 million licensing transaction with SERB Pharmaceuticals for its kidney transplant drug in Europe and MENA.  Idefirix is a first-in-class treatment that specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six hours. It is conditionally authorised by… Read More

#Business & Investment #News